![Emily Crossley](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Emily Crossley
Vorstandsvorsitzender bei Duchenne UK
Aktive Positionen von Emily Crossley
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Duchenne UK
![]() Duchenne UK Investment Trusts/Mutual FundsMiscellaneous Duchenne UK is a UK-based charity that focuses on finding effective treatments for Duchenne muscular dystrophy (DMD), a progressive condition that weakens all the muscles in the body and is diagnosed in childhood. Additionally, Duchenne connects and supports families affected by DMD. The charity funds research that aims to provide treatments for those affected by DMD and removes roadblocks that prevent patients from accessing the treatments they need. The British company was founded in 2012 by Nick Crossley, Emily Crossley, and Alex Johnson, and Emily Crossley and Alex Johnson have been the CEOs since 2012. | Vorstandsvorsitzender | 01.01.2012 | - |
Gründer | 01.01.2012 | - | |
Duchenne Research (UK) Investment Ltd.
![]() Duchenne Research (UK) Investment Ltd. BiotechnologyHealth Technology Duchenne Research (UK) Investment Ltd. is a biotechnology research and British experimental development company founded in 2014. The location of the private company is not specified. The company provides services in the field of biotechnology research and development. | Direktor/Vorstandsmitglied | 05.01.2016 | - |
Karriereverlauf von Emily Crossley
Statistik
International
Vereinigtes Königreich | 3 |
Operativ
Chief Executive Officer | 1 |
Founder | 1 |
Director/Board Member | 1 |
Sektoral
Miscellaneous | 2 |
Health Technology | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 2 |
---|---|
Duchenne UK
![]() Duchenne UK Investment Trusts/Mutual FundsMiscellaneous Duchenne UK is a UK-based charity that focuses on finding effective treatments for Duchenne muscular dystrophy (DMD), a progressive condition that weakens all the muscles in the body and is diagnosed in childhood. Additionally, Duchenne connects and supports families affected by DMD. The charity funds research that aims to provide treatments for those affected by DMD and removes roadblocks that prevent patients from accessing the treatments they need. The British company was founded in 2012 by Nick Crossley, Emily Crossley, and Alex Johnson, and Emily Crossley and Alex Johnson have been the CEOs since 2012. | Miscellaneous |
Duchenne Research (UK) Investment Ltd.
![]() Duchenne Research (UK) Investment Ltd. BiotechnologyHealth Technology Duchenne Research (UK) Investment Ltd. is a biotechnology research and British experimental development company founded in 2014. The location of the private company is not specified. The company provides services in the field of biotechnology research and development. | Health Technology |
- Börse
- Insiders
- Emily Crossley
- Erfahrung